Cargando…

Targeting mutant BRAF in colorectal cancer

Detalles Bibliográficos
Autores principales:	Carroll, David, Carson, R, Van Schaeybroeck, S, Johnston, PG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582887/ http://dx.doi.org/10.1186/1753-6561-7-S1-O8

Ejemplares similares

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

Emerging treatment options for BRAF-mutant colorectal cancer
por: Ursem, Carling, et al.
Publicado: (2018)

Development of a pharmacorphore model for pharmacological chaperones targeting mutant trafficking-deficient CNG channels
por: Schärfe, Charlotta PI, et al.
Publicado: (2013)

Therapeutic targeting truncated adenomatous polyposis coli (APC) proteins for the selective killing of colorectal cancer cells
por: Zhang, Lu, et al.
Publicado: (2014)

Screening & staging of colorectal cancer
por: Schima, Wolfgang, et al.
Publicado: (2014)

Combination drug development in BRAF mutant colorectal cancer
por: Lam, Michael, et al.
Publicado: (2018)

The Mutant Mouse Regional Resource Center Program
por: Lloyd, KCK
Publicado: (2003)

Phenotypes of sGC mutant mice in basic conditions, disease and shock
por: Brouckaert, Peter, et al.
Publicado: (2009)

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
por: Tran, Khanh B., et al.
Publicado: (2022)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Identifying dominant modifiers of mutant FUS toxicity in vivo
por: Daigle, J Gavin, et al.
Publicado: (2013)

Simultaneous reconstructive surgery for radical mastectomy
por: Robb, PG
Publicado: (2005)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

GUCY2C at the intersection of obesity and colorectal cancer
por: Waldman, Scott A, et al.
Publicado: (2013)

Adjuvant therapy in colorectal cancer – studies of the FOGT group
por: Staib, Ludger, et al.
Publicado: (2010)

Clinical and neuropathological evolution of the hydrocephalus developed by the mutant mouse hyh
por: Bátiz, Federico, et al.
Publicado: (2005)

Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
por: Bond, Catherine E., et al.
Publicado: (2012)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer
por: Neklason, Deborah W, et al.
Publicado: (2010)

Colorectal cancer in hyperplastic polyposis syndrome: In search of the polyp of origin
por: Rosty, Christophe, et al.
Publicado: (2011)

Tumor-tailored treatment of colorectal cancer: from bench to bedside?
por: Kornmann, Marko
Publicado: (2010)

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
por: Yan, Yibing, et al.
Publicado: (2014)

Translating breast cancer research into clinical practice — new approaches and better outcomes
por: Johnston, SRD
Publicado: (2006)

A predictive model of metachronous colorectal cancer occurrence in Lynch syndrome
por: Bertario, Lucio, et al.
Publicado: (2010)

Live imaging of Rab8 trafficking defects in cc2d2a mutant zebrafish
por: Bachmann-Gagescu, R, et al.
Publicado: (2012)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
por: Pan, Jing-hua, et al.
Publicado: (2018)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Activation of CDK4 by Tax chemosensitizes p53-mutant cells to DNA damage
por: Semmes, O John, et al.
Publicado: (2014)

APC Mutation Marks an Aggressive Subtype of BRAF Mutant Colorectal Cancers
por: Fennell, Lochlan J., et al.
Publicado: (2020)

Long-lasting hydrocephalus in hyh mutant mice: gain and loss of a brain surviving hydrocephalus
por: Rodríguez, Esteban M, et al.
Publicado: (2006)

The treatment of adolescent idiopathic scoliosis with Cheneau brace: long term outcome
por: Cinnella, P, et al.
Publicado: (2009)

Deciphering the molecular pathways disrupted in normal and neoplastic colonic tissue in inherited colorectal cancer syndromes
por: Neklason, Deborah W, et al.
Publicado: (2011)

Metachronous colorectal cancer risk for mismatch repair gene mutation carriers – the advantage of more extensive surgery
por: Parry, Susan, et al.
Publicado: (2011)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
por: Ascierto, Paolo A, et al.
Publicado: (2015)

Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy
por: Roy, R, et al.
Publicado: (2010)

Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
por: Angelis, Aris, et al.
Publicado: (2015)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

The EGF receptor family as targets for breast cancer therapy
por: Baselga, J
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_75l8k25ub0ije606vl4e297i61